Multicancer Early detection Panels (MCEDs) in the Primary Care Setting


      Multicancer early detection panels have recently become available to patients with a provider's prescription and an out-of-pocket fee. Beyond theoretical modeling, little is known about how these assays will impact primary care practices despite a high likelihood that primary care providers (PCPs) will be ordering these tests with some frequency. In particular, there are concerns about patient counseling, costs, frequency of testing, patient anxiety, and subsequent testing for a positive result. This review aims to appraise the current literature and provide a framework that PCPs can use to discuss these tests with patients and streamline their ordering, interpretation, and overall use into everyday practice.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to The American Journal of Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Etzioni R
        • Gulati R
        • Weiss NS
        Multi-cancer early detection: learning from the past to meet the future.
        J Natl Cancer Inst. 2022; 114: 349-352
        • Dasari A
        • Grothey A
        • Kopetz S
        Circulating tumor DNA-defined minimal residual disease in solid tumors: opportunities to accelerate the development of adjuvant therapies.
        J Clin Oncol. 2018; 36JCO2018789032
        • Pantel K
        • Alix-Panabieres C
        Liquid biopsy and minimal residual disease - latest advances and implications for cure.
        Nat Rev Clin Oncol. 2019; 16: 409-424
        • Liu MC
        • Oxnard GR
        • Klein EA
        • Swanton C
        • Seiden MV
        • Consortium C
        Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA.
        Ann Oncol. 2020; 31: 745-759
        • Klein EA
        • Richards D
        • Cohn A
        • et al.
        Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set.
        Ann Oncol. 2021; 32: 1167-1177
        • Hubbell E
        • Clarke CA
        • Aravanis AM
        • Berg CD
        Modeled reductions in late-stage cancer with a multi-cancer early detection test.
        Cancer Epidemiol Biomark Prev. 2021; 30: 460-468
        • Cohen JD
        • Li L
        • Wang Y
        • et al.
        Detection and localization of surgically resectable cancers with a multi-analyte blood test.
        Science. 2018; 359: 926-930
        • Lennon AM
        • Buchanan AH
        • Kinde I
        • et al.
        Feasibility of blood testing combined with PET-CT to screen for cancer and guide intervention.
        Science. 2020; 369
      1. Galleri, Inc. Test pricing and benefit coverage. Available at: Published 2022. Accessed January 7, 2022.

      2. Bloomberg Media. GRAIL receives New York State approval for Galleri multi-cancer early detection blood test. Available at: September 21, 2021. Accessed January7, 2022.

      3., 117th Congress. H.R.1946 - Medicare Multi-Cancer Early Detection Screening Coverage Act of 2021. United States Congress. Available at: Updated March 16, 2021. Accessed January 7, 2022.

        • Chen XJ
        • Dong Z
        • Hubbell E
        • et al.
        Prognostic significance of blood-based multi-cancer detection in plasma cell-free DNA.
        Clin Cancer Res. 2021; 27: 4221-4229
        • Fiala C
        • Diamandis EP
        Can a broad molecular screen based on circulating tumor DNA aid in early cancer detection?.
        J Appl Lab Med. 2020; 5: 1372-1377